<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03639519</url>
  </required_header>
  <id_info>
    <org_study_id>GMMC-RC18-2</org_study_id>
    <nct_id>NCT03639519</nct_id>
  </id_info>
  <brief_title>A Trial to Assess the Impact of Ascorbic Acid on Cardiac Surgeries Outcomes and Complications''</brief_title>
  <official_title>'A Prospective Randomized Trial to Assess the Impact of Ascorbic Acid on Outcomes and Complications Post Cardiac Surgeries''</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>El-Galaa Military Medical Complex</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>El-Galaa Military Medical Complex</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      this study is evaluating the safety and efficacy of ascorbic acid as a drug that can decrease
      inflammatory complications post surgical in addition to its impact on decreasing risk of
      arrhythmia and total opioid administration post operative
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will include two arm of patients who are scheduled for elective cardiac surgery,
      either coronary artery bypass grafting (CABG) or Valvular replacement First arm: Patients
      will take 2 g orally ascorbic acid effervescent tablets the night before cardiac surgery,
      then 1 g twice daily for 5 days after surgery in addition to their traditional medical care.
      Second arm: will not be given ascorbic acid , instead a placebo 9orange carbonated beverage)
      will be used, and will be given the rest of traditional medical care provided to the first
      arm. Inflammatory markers C- reactive protein (CRP), erythrocyte sedimentation rate (ESR) and
      differential total leukocytic count (TLC), serum urea and creatinine, ALT, AST, CK-mb,
      CK-Total, aPTT, INR, Hemoglobin, platelet count, will be assessed on day 0, 1,2,4,6
      postoperative in both arms.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 15, 2018</start_date>
  <completion_date type="Anticipated">August 15, 2019</completion_date>
  <primary_completion_date type="Anticipated">April 15, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Risk of arrhythmia post operative</measure>
    <time_frame>7 days post operative</time_frame>
    <description>assessing risk of AF post surgical using ECG</description>
  </primary_outcome>
  <primary_outcome>
    <measure>pain management</measure>
    <time_frame>2 days post operative</time_frame>
    <description>Evaluating cumulative dose of opioid administered within ICU stay in the two groups</description>
  </primary_outcome>
  <primary_outcome>
    <measure>wound healing</measure>
    <time_frame>30 days post operative</time_frame>
    <description>assessment of wound inflammation and infection risk using ASEPSIS score (a scoring system to assess wound healing and evaluate the presence of infection, a score between 10 to 20 means disturbed healing, &gt;20 points means infected wound, &gt;30 means moderate to sever infection)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Cardiothoracic Surgery</condition>
  <arm_group>
    <arm_group_label>Ascorbic acid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will take 2 g orally ascorbic acid effervescent tablets the night before cardiac surgery, then 1 g twice daily for 5 days after surgery in addition to their traditional medical care.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>will not be given ascorbic acid , instead a placebo will be used, and will be given the rest of traditional medical care provided to the first arm. Inflammatory markers (CRP, ESR and differential TLC), serum urea and creatinine, ALT, AST, CK-mb, CK-Total, aPTT, INR, Hemoglobin, platelet count, will be assessed on day 0, 1,2,4,6 postoperative in both arms.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ascorbic Acid 500Mg Chew Tab</intervention_name>
    <description>Ascorbic acid will be administered at the night before surgery and will be continued for five days</description>
    <arm_group_label>Ascorbic acid</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Carbonated orange beverage</intervention_name>
    <description>The carbonated orange beverage will be administered at the night before surgery and will be continued for five days</description>
    <arm_group_label>Placebo group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Elective Cardiac surgery

          -  American Society of Anesthesiologists physical status class I-III

        Exclusion Criteria:

          -  Allergy to ascorbic acid

          -  Asthma

          -  COPD

          -  Allergy to opioids

          -  Previous history of chemical dependence

          -  Prior cardiac surgery

          -  Known hyperoxaluria

          -  History of renal calculi

          -  History of allergic or hypersensitivity reaction to ascorbic acid products

          -  Currently taking 1 g or more of ascorbic acid supplementation daily
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Tamer M Ayed, MD</last_name>
    <phone>01006045615</phone>
    <email>Tamerayed70@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Galaa Military Medical Complex</name>
      <address>
        <city>Cairo</city>
        <state>Sheraton</state>
        <zip>11651</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tamer M Ayed, MD</last_name>
    </contact>
    <investigator>
      <last_name>Tamer M Ayed, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Walid R Abdelfattah, MSc</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nehal A Hassan, MSc</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Fathi M Aboushareb, MSc</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nourhane A Ibrahim, MSc</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kareem E Eltoukhy, MSc</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Romel B Barsoum, MSc</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Maged A Mohamed, MSc</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>George S Hanna, BSc</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>August 13, 2018</study_first_submitted>
  <study_first_submitted_qc>August 19, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 21, 2018</study_first_posted>
  <last_update_submitted>August 19, 2018</last_update_submitted>
  <last_update_submitted_qc>August 19, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 21, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ascorbic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

